Social and Economic Costs of Attention-Deficit/Hyperactivity Disorder Across the Lifespan

Objective: To determine the financial and non-financial costs of Attention-Deficit/Hyperactivity Disorder (ADHD) across the lifespan. Method: The population costs of ADHD in Australia were estimated for the financial year 2018 to 2019 using a prevalence approach to cost estimation across all ages. Financial (healthcare, productivity, education and justice systems, and deadweight losses) and non-financial costs were measured (Disability Adjusted Life Years (DALYs)). Results: The total social and economic cost of ADHD in 2018 to 2019 were US$12.76 billion (range US$8.40 billion to US$17.44 billion, with per person costs of US$15,664 per year). Productivity costs made up 81% of the total financial costs, followed by deadweight losses (11%), and health system costs (4%). Loss in terms of wellbeing was significant (US$5.31 billion). Conclusion: There is a need to raise public awareness of the considerable socioeconomic impact and burden of ADHD in order to drive investment and policy decisions that improve identification and treatment of ADHD.

[1]  I. Oh,et al.  Economic Burden and Disability-Adjusted Life Years (DALYs) of Attention Deficit/Hyperactivity Disorder , 2020, Journal of attention disorders.

[2]  T. Ford.  Transitional care for young adults with ADHD: transforming potential upheaval into smooth progression , 2020, Epidemiology and Psychiatric Sciences.

[3]  P. Bendtsen,et al.  Comorbidity of Adult ADHD and Its Subtypes With Substance Use Disorder in a Large Population-Based Epidemiological Study , 2019, Journal of attention disorders.

[4]  D. Coghill.  Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term? (For). , 2019, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  D. Daley,et al.  The economic burden of adult attention deficit hyperactivity disorder: A sibling comparison cost analysis , 2019, European Psychiatry.

[6]  W. Pelham,et al.  Family Burden of Raising a Child with ADHD , 2019, Journal of Abnormal Child Psychology.

[7]  T. Ford,et al.  Transition between child and adult services for young people with attention-deficit hyperactivity disorder (ADHD): findings from a British national surveillance study , 2019, The British Journal of Psychiatry.

[8]  H. Tuomainen,et al.  Outcomes of young people who reach the transition boundary of child and adolescent mental health services: a systematic review , 2019, European Child & Adolescent Psychiatry.

[9]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[10]  H. Hiscock,et al.  Factors Associated With Educational Support in Young Adolescents With ADHD , 2018, Journal of attention disorders.

[11]  S. Dalsgaard,et al.  Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study , 2018, PloS one.

[12]  J. Swanson,et al.  Treatment strategies for ADHD: an evidence-based guide to select optimal treatment , 2018, Molecular Psychiatry.

[13]  C. Hollis.  ADHD and transitions to adult mental health services , 2018, Oxford Medicine Online.

[14]  M. Danckaerts,et al.  Oxford Textbook of Attention Deficit Hyperactivity Disorder , 2018, Oxford Medicine Online.

[15]  Anthony Morgan.  How much does prison really cost? Comparing the costs of imprisonment with community corrections , 2018 .

[16]  J. Alda,et al.  Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis , 2018, BMC Psychiatry.

[17]  H. Hiscock,et al.  Health Care Costs Associated With Parent-Reported ADHD: A Longitudinal Australian Population–Based Study , 2017, Journal of attention disorders.

[18]  K. Lawson,et al.  Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  James G. Scott,et al.  Long-Term Outcomes of Attention-Deficit/Hyperactivity Disorder and Conduct Disorder: A Systematic Review and Meta-Analysis. , 2016, Journal of the American Academy of Child and Adolescent Psychiatry.

[20]  V. Harpin,et al.  The Caregiver Perspective on Paediatric ADHD (CAPPA) survey: Understanding sociodemographic and clinical characteristics, treatment use and impact of ADHD in Europe. , 2016, Journal of affective disorders.

[21]  S. Faraone,et al.  Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies , 2016, Molecular Psychiatry.

[22]  S. Zubrick,et al.  Service use by Australian children for emotional and behavioural problems: Findings from the second Australian Child and Adolescent Survey of Mental Health and Wellbeing , 2016, The Australian and New Zealand journal of psychiatry.

[23]  E. Simonsen,et al.  Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials , 2015, BMJ : British Medical Journal.

[24]  M. Fazel.  Methylphenidate for ADHD , 2015, BMJ : British Medical Journal.

[25]  D. Efron,et al.  Service use in children aged 6–8 years with attention deficit hyperactivity disorder , 2015, Archives of Disease in Childhood.

[26]  S. Zubrick,et al.  The Mental Health of Children and Adolescents: Report on the second Australian Child and Adolescent Survey of Mental Health and Wellbeing , 2015 .

[27]  S. Dalsgaard,et al.  Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study , 2015, The Lancet.

[28]  L. Cao,et al.  Understanding the economy wide efficiency and incidence of major Australian taxes , 2015 .

[29]  K. Merikangas,et al.  Impact of the DSM-5 attention-deficit/hyperactivity disorder age-of-onset criterion in the US adolescent population. , 2014, Journal of the American Academy of Child and Adolescent Psychiatry.

[30]  G. Salum,et al.  ADHD in DSM-5: a field trial in a large, representative sample of 18- to 19-year-old adults , 2014, Psychological Medicine.

[31]  E. Taylor,et al.  Use of services and associated costs for young adults with childhood hyperactivity/conduct problems: 20-year follow-up , 2014, British Journal of Psychiatry.

[32]  H. Hiscock,et al.  Anxiety in Children With Attention-Deficit/Hyperactivity Disorder , 2014, Pediatrics.

[33]  James G. Scott,et al.  The global burden of conduct disorder and attention-deficit/hyperactivity disorder in 2010. , 2014, Journal of child psychology and psychiatry, and allied disciplines.

[34]  M. Postma,et al.  Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case , 2013, European Child & Adolescent Psychiatry.

[35]  D. Coghill,et al.  The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010) , 2013, Child and Adolescent Psychiatry and Mental Health.

[36]  D. Duffy,et al.  Attention Deficit Hyperactivity Disorder in Australian Adults: Prevalence, Persistence, Conduct Problems and Disadvantage , 2012, PloS one.

[37]  Peter J Neumann,et al.  Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. , 2012, Journal of the American Academy of Child and Adolescent Psychiatry.

[38]  H. Caci,et al.  A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment , 2012, BMC Medicine.

[39]  Joshua M. Langberg,et al.  Does Long-Term Medication Use Improve the Academic Outcomes of Youth with Attention-Deficit/Hyperactivity Disorder? , 2012, Clinical child and family psychology review.

[40]  N. Halfon,et al.  Patterns of Comorbidity, Functioning, and Service Use for US Children With ADHD, 2007 , 2011, Pediatrics.

[41]  C. Advokat.  What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD) , 2010, Neuroscience & Biobehavioral Reviews.

[42]  M. Schlander,et al.  [The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness]. , 2010, Der Nervenarzt.

[43]  William E Pelham,et al.  The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. , 2007, Ambulatory pediatrics : the official journal of the Ambulatory Pediatric Association.

[44]  B. Horta,et al.  The worldwide prevalence of ADHD: a systematic review and metaregression analysis. , 2007, The American journal of psychiatry.

[45]  M. Prasad,et al.  A review of the economic burden of ADHD , 2005, Cost effectiveness and resource allocation : C/E.

[46]  T. B. Üstün,et al.  The Prevalence and Effects of Adult Attention Deficit/Hyperactivity Disorder on Work Performance in a Nationally Representative Sample of Workers , 2005, Journal of occupational and environmental medicine.

[47]  K. Secnik,et al.  Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder , 2005, PharmacoEconomics.

[48]  P. Mayhew,et al.  Counting the costs of crime in Australia , 2003 .

[49]  Eugenia Chan,et al.  Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. , 2002, Archives of pediatrics & adolescent medicine.

[50]  Australian Employers,et al.  THE COST OF WORK-RELATED INJURY AND ILLNESS FOR , 2012 .

[51]  M. Willoughby.  Developmental course of ADHD symptomatology during the transition from childhood to adolescence: a review with recommendations. , 2003, Journal of child psychology and psychiatry, and allied disciplines.